Discovery, Design, and Synthesis of Novel 2-Benzyl-2,7-diazaspiro[3.5]nonane Benzothiazinones with Broad-Spectrum Antimycobacterial Activity
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c02429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Jizhou Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Hauptthemen laut MEDLINE: Thiazines, Drug Design, Antitubercular Agents, Drug Discovery. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences, Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Despite their nanomolar potency against M. tuberculosis (MTB), benzothiazinone (BTZs) DprE1 inhibitors like PBTZ169 are ineffective against nontuberculous mycobacteria (NTM) due to a Cys387Ala mutation in the NTM DprE1 target. Here, 529 BTZs in our lab were screened againstM. abscessus, and two hits with the 2-benzyl-2,7-diazaspiro[3.5]nonane scaffold showed enhanced activity. Subsequent optimization led to the discovery of lead compound B2 with potent activity against MTB (MIC: < 0.01 μg/mL) and NTM strains (MIC: < 0.03125-2.5 μg/mL). Notably, B2 also has good safety and oral pharmacokinetic (PK) profiles. Further chiral resolution revealed its R-enantiomer (B2-1) as a more active form. Mechanistic investigations showed that B2-1 establishes a stable electrostatic interaction with Asp326 ofM. abscessusDprE1. As this residue is highly conserved among mycobacterial species, such an interaction likely underpins its broad-spectrum activity. Therefore, our findings provide a blueprint for developing next-generation BTZs with broad-spectrum activity against mycobacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Department of Tuberculosis, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing 210003, China.
- Clinical Research Center, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing 210003, China.
- MindRank AI Ltd., Hangzhou 310000, China.
ORCID-Profile: Mingliang Liu, Apeng Wang
Förderung
- Chinese Academy of Medical Sciences
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Nanjing Municipal Health Bureau
- Talent Lift Foundation of the Second Hospital of Nanjing
Zitieren
APA
Wu, J., Ma, C., Wei, M., Chen, X., Wang, W., Gao, J., Huang, J., Ji, X., Wei, M., Liu, M., Wang, A., Lv, K., & Chen, W. (2025). Discovery, Design, and Synthesis of Novel 2-Benzyl-2,7-diazaspiro[3.5]nonane Benzothiazinones with Broad-Spectrum Antimycobacterial Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02429
Vancouver
Wu J, Ma C, Wei M, Chen X, Wang W, Gao J, et al. Discovery, Design, and Synthesis of Novel 2-Benzyl-2,7-diazaspiro[3.5]nonane Benzothiazinones with Broad-Spectrum Antimycobacterial Activity. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02429
BibTeX
@article{Wu2025,
author = {Wu, Jizhou and Ma, Chao and Wei, Meng and Chen, Xiuzhen and Wang, Weixiao and Gao, Jinghan and Huang, Junjie and Ji, Xiaorui and Wei, Meijiao and Liu, Mingliang and Wang, Apeng and Lv, Kai and Chen, Wei},
title = {Discovery, Design, and Synthesis of Novel 2-Benzyl-2,7-diazaspiro[3.5]nonane Benzothiazinones with Broad-Spectrum Antimycobacterial Activity},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c02429}
}
EUVIMED